Cargando…

Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi

Current eligibility criteria for urine lateral-flow lipoarabinomannan assay (LF-LAM) in ambulatory, HIV-positive patients rely on the CD4 count. We investigated the diagnostic yield of LF-LAM and the 6-month mortality in ambulatory, TB symptomatic, HIV-positive patients regardless of their CD4 count...

Descripción completa

Detalles Bibliográficos
Autores principales: Huerga, Helena, Rucker, Sekai Chenai Mathabire, Bastard, Mathieu, Dimba, Andrew, Kamba, Cosmas, Amoros, Isabel, Szumilin, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903332/
https://www.ncbi.nlm.nih.gov/pubmed/31633613
http://dx.doi.org/10.1097/QAI.0000000000002206
_version_ 1783477833026240512
author Huerga, Helena
Rucker, Sekai Chenai Mathabire
Bastard, Mathieu
Dimba, Andrew
Kamba, Cosmas
Amoros, Isabel
Szumilin, Elisabeth
author_facet Huerga, Helena
Rucker, Sekai Chenai Mathabire
Bastard, Mathieu
Dimba, Andrew
Kamba, Cosmas
Amoros, Isabel
Szumilin, Elisabeth
author_sort Huerga, Helena
collection PubMed
description Current eligibility criteria for urine lateral-flow lipoarabinomannan assay (LF-LAM) in ambulatory, HIV-positive patients rely on the CD4 count. We investigated the diagnostic yield of LF-LAM and the 6-month mortality in ambulatory, TB symptomatic, HIV-positive patients regardless of their CD4 count. METHODS: We conducted a prospective, observational study that included all ambulatory, ≥15-year-old, TB symptomatic (cough, weight loss, fever, or night sweats) HIV-positive patients presenting at 4 health facilities in Malawi. Patients received a clinical examination and were requested urine LF-LAM, sputum microscopy, and Xpert MTB/RIF. TB was defined as bacteriologically confirmed if Xpert was positive. RESULTS: Of 485 patients included, 171 (35.3%) had a CD4 <200 and 32 (7.2%) were seriously ill. Median CD4 count was 341 cells/µL (interquartile range: 129–256). LAM was positive in 24.9% patients with CD4 < 200 (50% LAM grades 2–4) and 12.5% with CD4 ≥ 200 (12.8% LAM grades 2–4). Xpert was positive in 14.1% (44/312). Among Xpert-positive patients, LAM positivity was 56.7% (CD4 < 200) and 42.9% (CD4 ≥ 200), P = 0.393. Of the patients without an Xpert result, 13.4% (23/172) were LAM positive (ie, potentially missed patients). Overall, mortality was 9.2% (44/478). More pronounced LAM-positive patients had higher mortality than LAM-negative (grades 2–4: 36.0%; grade 1: 9.1%; negative: 7.4%; P < 0.001). LAM-positive patients with CD4 <200 cells/µL had higher risk of mortality than LAM negatives (adjusted hazard ratio: 3.2, 95% confidence interval: 1.4 to 7.2, P = 0.006), particularly those with LAM grades 2–4 (adjusted hazard ratio: 4.9, 95% confidence interval: 1.8 to 13.3, P = 0.002). CONCLUSIONS: Urine-LAM testing can be useful for TB diagnosis in HIV-positive TB-symptomatic patients with no CD4 cell count. LAM grade can identify patients at higher risk of death in this situation.
format Online
Article
Text
id pubmed-6903332
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher JAIDS Journal of Acquired Immune Deficiency Syndromes
record_format MEDLINE/PubMed
spelling pubmed-69033322020-01-22 Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi Huerga, Helena Rucker, Sekai Chenai Mathabire Bastard, Mathieu Dimba, Andrew Kamba, Cosmas Amoros, Isabel Szumilin, Elisabeth J Acquir Immune Defic Syndr Implementation Science Current eligibility criteria for urine lateral-flow lipoarabinomannan assay (LF-LAM) in ambulatory, HIV-positive patients rely on the CD4 count. We investigated the diagnostic yield of LF-LAM and the 6-month mortality in ambulatory, TB symptomatic, HIV-positive patients regardless of their CD4 count. METHODS: We conducted a prospective, observational study that included all ambulatory, ≥15-year-old, TB symptomatic (cough, weight loss, fever, or night sweats) HIV-positive patients presenting at 4 health facilities in Malawi. Patients received a clinical examination and were requested urine LF-LAM, sputum microscopy, and Xpert MTB/RIF. TB was defined as bacteriologically confirmed if Xpert was positive. RESULTS: Of 485 patients included, 171 (35.3%) had a CD4 <200 and 32 (7.2%) were seriously ill. Median CD4 count was 341 cells/µL (interquartile range: 129–256). LAM was positive in 24.9% patients with CD4 < 200 (50% LAM grades 2–4) and 12.5% with CD4 ≥ 200 (12.8% LAM grades 2–4). Xpert was positive in 14.1% (44/312). Among Xpert-positive patients, LAM positivity was 56.7% (CD4 < 200) and 42.9% (CD4 ≥ 200), P = 0.393. Of the patients without an Xpert result, 13.4% (23/172) were LAM positive (ie, potentially missed patients). Overall, mortality was 9.2% (44/478). More pronounced LAM-positive patients had higher mortality than LAM-negative (grades 2–4: 36.0%; grade 1: 9.1%; negative: 7.4%; P < 0.001). LAM-positive patients with CD4 <200 cells/µL had higher risk of mortality than LAM negatives (adjusted hazard ratio: 3.2, 95% confidence interval: 1.4 to 7.2, P = 0.006), particularly those with LAM grades 2–4 (adjusted hazard ratio: 4.9, 95% confidence interval: 1.8 to 13.3, P = 0.002). CONCLUSIONS: Urine-LAM testing can be useful for TB diagnosis in HIV-positive TB-symptomatic patients with no CD4 cell count. LAM grade can identify patients at higher risk of death in this situation. JAIDS Journal of Acquired Immune Deficiency Syndromes 2020-01-01 2019-10-16 /pmc/articles/PMC6903332/ /pubmed/31633613 http://dx.doi.org/10.1097/QAI.0000000000002206 Text en Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Implementation Science
Huerga, Helena
Rucker, Sekai Chenai Mathabire
Bastard, Mathieu
Dimba, Andrew
Kamba, Cosmas
Amoros, Isabel
Szumilin, Elisabeth
Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi
title Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi
title_full Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi
title_fullStr Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi
title_full_unstemmed Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi
title_short Should Urine-LAM Tests Be Used in TB Symptomatic HIV-Positive Patients When No CD4 Count Is Available? A Prospective Observational Cohort Study From Malawi
title_sort should urine-lam tests be used in tb symptomatic hiv-positive patients when no cd4 count is available? a prospective observational cohort study from malawi
topic Implementation Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903332/
https://www.ncbi.nlm.nih.gov/pubmed/31633613
http://dx.doi.org/10.1097/QAI.0000000000002206
work_keys_str_mv AT huergahelena shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi
AT ruckersekaichenaimathabire shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi
AT bastardmathieu shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi
AT dimbaandrew shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi
AT kambacosmas shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi
AT amorosisabel shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi
AT szumilinelisabeth shouldurinelamtestsbeusedintbsymptomatichivpositivepatientswhennocd4countisavailableaprospectiveobservationalcohortstudyfrommalawi